Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1, -2, and -3 clinical trials.
about
Hepatocellular carcinoma: Where are we?Update on hepatitis C: Direct-acting antiviralsThe changing landscape of hepatitis C virus therapy: focus on interferon-free treatmentPatient-reported and economic outcomes related to sofosbuvir and ledipasvir treatment for chronic hepatitis C.Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health study.Ledipasvir/Sofosbuvir: a review of its use in chronic hepatitis C.Hepatitis C virus infection, and neurological and psychiatric disorders - A review.Patient-reported Outcomes in Asian Patients With Chronic Hepatitis C Treated With Ledipasvir and Sofosbuvir.Economic and Public Health Impacts of Policies Restricting Access to Hepatitis C Treatment for Medicaid Patients.CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core Research Group: 2016 Updated Canadian HIV/Hepatitis C Adult Guidelines for Management and TreatmentThe levels of monoamine neurotransmitters and measures of mental and emotional health in HCV patients treated with ledipasvir (LDV) and sofosbuvir (SOF) with or without ribavirin (RBV).Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive study.Ribavirin revisited in the era of direct-acting antiviral therapy for hepatitis C virus infection.Health utilities using SF-6D scores in Japanese patients with chronic hepatitis C treated with sofosbuvir-based regimens in clinical trialsQuality of life of Japanese patients with chronic hepatitis C treated with ledipasvir and sofosbuvir.Safety analysis of sofosbuvir and ledipasvir for treating hepatitis C.Extrahepatic manifestations of HCV: the role of direct acting antivirals.In Vitro Antiviral Activity and Resistance Profile Characterization of the Hepatitis C Virus NS5A Inhibitor LedipasvirCost-Effectiveness Modelling of Sofosbuvir-Containing Regimens for Chronic Genotype 5 Hepatitis C Virus Infection in South Africa.Superiority of Interferon-Free Regimens for Chronic Hepatitis C: The Effect on Health-Related Quality of Life and Work Productivity.Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real-world cohort study.Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials.Sofosbuvir and ledipasvir improve patient-reported outcomes in patients co-infected with hepatitis C and human immunodeficiency virus.In an era of highly effective treatment, hepatitis C screening of the United States general population should be considered.Patient-reported outcomes in patients co-infected with hepatitis C virus and human immunodeficiency virus treated with sofosbuvir and velpatasvir: The ASTRAL-5 study.Direct antiviral agent treatment of decompensated hepatitis C virus-induced liver cirrhosisNew resistance-associated substitutions and failure of dual oral therapy with daclatasvir and asunaprevir.Impact of eradicating hepatitis C virus on the work productivity of chronic hepatitis C (CH-C) patients: an economic model from five European countries.The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons.The impact of ledipasvir/sofosbuvir on patient-reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study.Quality of Life in Adolescents with Hepatitis C Treated with Sofosbuvir and Ribavirin.Efficacy and Safety of Direct-acting Antivirals in Hepatitis C Virus-infected Patients Taking Proton Pump Inhibitors.Sofosbuvir and velpatasvir with or without voxilaprevir in direct-acting antiviral-naïve chronic hepatitis C: patient-reported outcomes from POLARIS 2 and 3.Current and future challenges in HCV: insights from an Italian experts panel.Impact of ledipasvir/sofosbuvir on the work productivity of genotype 1 chronic hepatitis C patients in Asia.Advanced Prodrug Strategies in Nucleoside and Non-Nucleoside Antiviral Agents: A Review of the Recent Five Years.Transmission genetics of drug-resistant hepatitis C virus.Direct-acting antiviral treatment in real world patients with hepatitis C not associated with psychiatric side effects: a prospective observational study.Health-Related Quality of Life in Chronic Hepatitis C.The Impact of Hepatitis C Virus Direct-Acting Antivirals on Patient-Reported Outcomes: A Dutch Prospective Cohort Study
P2860
Q26765182-14EC8A04-EE20-4A43-A0A6-C4B08B374D2CQ26775809-243798A8-5AC0-4984-A969-ECD4D3FD67B9Q26795559-D17A9FA7-4068-4EC0-A8DC-846B0A1EF154Q30393824-D8F73732-EE43-4555-A2C5-B35C34FD0124Q33435950-9585AA2C-6B7E-4F14-A8F9-37B2B2F6CBA5Q34470061-AD0CC85F-6743-4537-8238-4CE4E4CF782BQ36266948-D3315799-AFE2-4E7D-9035-32895001B7A2Q36663835-F14D292A-D356-450C-83FB-1A45BC203240Q37027342-18082399-2EDD-4B4D-80A0-9A9575B03BF1Q37100669-2A431E3D-EF5E-4035-9E67-AE79C0AE63E5Q37432877-4E03162B-48FD-45FF-8D8A-9734A797D826Q37521046-6745D1FE-8CBA-4B17-A7E6-2F2D1E3418F7Q37563692-488B4E01-9EAA-4F1B-948C-5349A69C1592Q37615658-94CA3BAD-827B-4D81-91BB-E8FB23EED7B7Q37726632-5DB1F6FB-A0B5-418A-B7DC-DE1F19923A18Q38516135-2288E904-321B-4EFA-ADCA-41CCD9BFF812Q38684508-A96F2274-F2B1-479D-8D84-AE8ED0574ADCQ38740523-45711E54-30A8-44BE-80F0-E89EBC1C8CDDQ38932103-983F073E-D29B-4502-B767-2000B223196FQ38957601-2872F803-EEF4-44A5-A78D-AC6A8D6D0F87Q39481949-9CB59245-006E-4487-B081-B485FAFBF582Q39574126-03B23443-8773-4410-AE5C-50120E9D53C2Q39690321-4CBC7152-905B-4F65-B2C1-2F5CE77209D2Q40118666-B4C51AF1-FE19-4B86-B36E-06C677FB7169Q40215825-7CC006CE-E9D8-44F8-B5CF-2F54C9E52BDDQ40333567-43932100-2179-422B-AC1D-4C01D707DB73Q40375437-152A381D-1F4C-4ACF-A2F4-E9E469FCA628Q40414089-68833A27-9A01-42CA-8C52-85C4F6938EF7Q40773451-426BE8CF-B3E3-4F58-A2B4-652778A1B37CQ41682696-12115B00-0187-4942-93C0-FC1C90CB4317Q45074467-6C6CBB36-9457-45C8-B045-FA5E9E432153Q45323549-9B5F3D31-ABF7-4147-9737-26747BA9B7D0Q47404164-EF0E9915-4B25-48FA-8AB6-29F6D9E38480Q47591971-D6ECB640-5A9C-43DD-A174-43B117934AE9Q47605707-6372702E-C8E4-43CA-B906-6B2F215587CDQ47611417-220815C3-5B19-4F2C-9AFF-A0041DF341A4Q52339521-344CFFB4-FACB-47C4-9BAA-D900D271E893Q55050518-AEC19BD5-53B4-48A6-AAC7-AF5E0A1CDE99Q55361959-D1464652-1E0F-493E-AFC1-E6A5B94F0DF7Q58801171-B320CE43-6A21-44D7-BC2F-19C0FF0DF5AE
P2860
Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1, -2, and -3 clinical trials.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Treatment with ledipasvir and ...... 1, -2, and -3 clinical trials.
@en
Treatment with ledipasvir and ...... 1, -2, and -3 clinical trials.
@nl
type
label
Treatment with ledipasvir and ...... 1, -2, and -3 clinical trials.
@en
Treatment with ledipasvir and ...... 1, -2, and -3 clinical trials.
@nl
prefLabel
Treatment with ledipasvir and ...... 1, -2, and -3 clinical trials.
@en
Treatment with ledipasvir and ...... 1, -2, and -3 clinical trials.
@nl
P2093
P921
P356
P1433
P1476
Treatment with ledipasvir and ...... 1, -2, and -3 clinical trials.
@en
P2093
Kris V Kowdley
Maria Stepanova
Patrick Marcellin
Sharon L Hunt
Zobair M Younossi
P304
P356
10.1002/HEP.27724
P407
P577
2015-03-18T00:00:00Z